Factors associated with COVID-19 breakthrough infection among vaccinated patients with rheumatic diseases: A cohort study
Naomi J Patel, Xiaosong Wang, Xiaoqing Fu, Yumeko Kawano, Claire Cook, Kathleen M M Vanni, Grace Qian, Emily Banasiak, Emily Kowalski, Yuqing Zhang, Jeffrey A Sparks, Zachary S Wallace
Seminars in Arthritis and Rheumatism, doi:10.1016/j.semarthrit.2022.152108
This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
References
Ahmed, Mehta, Paul, Postvaccination antibody titres predict protection against COVID-19 in patients with autoimmune diseases: survival analysis in a prospective cohort, Ann Rheum Dis
Apostolidis, Kakara, Painter, Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy, Nat Med
Avouac, Drumez, Hachulla, COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study, Lancet Rheumatol
Bajema, Dahl, Evener, Comparative Effectiveness and Antibody Responses to Moderna and Pfizer-BioNTech COVID-19 Vaccines among Hospitalized Veterans -Five Veterans Affairs Medical Centers, United States, February 1, MMWR Morb Mortal Wkly Rep
Boekel, Stalman, Wieske, Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy of two prospective cohort studies, Lancet Rheumatol
Brosh-Nissimov, Orenbuch-Harroch, Chowers, BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients in Israel, Clin Microbiol Infect
Charlson, Pompei, Ales, Mackenzie, A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation, J Chron Dis
Cook, Patel, Silva, Clinical characteristics and outcomes of COVID-19 breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases, Ann Rheum Dis
Cook, Patel, Silva, Clinical characteristics and outcomes of COVID-19 breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases, Ann Rheum Dis
Cordtz, Kristensen, Westermann, COVID-19 infection and hospitalisation risk according to vaccination status and DMARD treatment in patients with rheumatoid arthritis, Rheumatology
Deepak, Kim, Paley, Glucocorticoids and B Cell Depleting Agents Substantially Impair Immunogenicity of mRNA Vaccines to SARS-CoV-2
Dickerman, Gerlovin, Madenci, Comparative Effectiveness of BNT162b2 and mRNA-1273 Vaccines in U.S. Veterans, N Engl J Med
Fragoulis, Karamanakos, Arida, Clinical outcomes of breakthrough COVID-19 after booster vaccination in patients with systemic rheumatic diseases, RMD Open
Friedman, Curtis, Winthrop, Impact of disease-modifying antirheumatic drugs on vaccine immunogenicity in patients with inflammatory rheumatic and musculoskeletal diseases, Ann Rheum Dis
Furer, Eviatar, Zisman, Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study, Ann Rheum Dis
Fusco, Moran, Cane, Evaluation of COVID-19 vaccine breakthrough infections among immunocompromised patients fully vaccinated with BNT162b2, J Med Econ
Grainger, Kim, Conway, Yazdany, Robinson, COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations, Nat Rev Rheumatol
Haberman, Herati, Simon, Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease, Ann Rheum Dis
Kim, Servi, Polinski, Validation of rheumatoid arthritis diagnoses in health care utilization data, Arthritis Res Ther
Lawson-Tovey, Hyrich, Gossec, SARS-CoV-2 infection after vaccination in patients with inflammatory rheumatic and musculoskeletal diseases, Ann Rheum Dis
Liew, Gianfrancesco, Harrison, SARS-CoV-2 Breakthrough Infections Among Vaccinated Individuals with Rheumatic Disease: Results From the COVID-19 Global Rheumatology Alliance Provider Registry, RMD Open
Mrak, Tobudic, Koblischke, SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity, Ann Rheum Dis
Nalichowski, Keogh, Chueh, Murphy, Calculating the Benefits of a Research Patient Data Repository, AMIA Annu Symp Proc
Paik, Sparks, Kim, Immunogenicity, breakthrough infection, and underlying disease flare after SARS-CoV-2 vaccination among individuals with systemic autoimmune rheumatic diseases, Curr Opin Pharmacol
Risk, Hayek, Schiopu, COVID-19 vaccine effectiveness against omicron (B.1.1.529) variant infection and hospitalisation in patients taking immunosuppressive medications: a retrospective cohort study, The Lancet Rheumatology
Serling-Boyd, Silva, Hsu, Coronavirus disease 2019 outcomes among patients with rheumatic diseases 6 months into the pandemic, Ann Rheum Dis
Silva, Boyd, Wallwork, Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US 'hot spot', Ann Rheum Dis
Simon, Tascilar, Schmidt, Humoral and Cellular Immune Responses to SARS-CoV-2 Infection and Vaccination in Autoimmune Disease Patients With B Cell Depletion, Arthritis Rheumatol
Sparks, Wallace, Seet, Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry, Ann Rheum Dis
Sun, Zheng, Madhira, Association Between Immune Dysfunction and COVID-19 Breakthrough Infection After SARS-CoV-2 Vaccination in the US, JAMA Intern Med
Widdifield, Kwong, Chen, Vaccine effectiveness against SARS-CoV-2 infection and severe outcomes among individuals with immune-mediated inflammatory diseases tested between March 1 and Nov 22, 2021, in Ontario, Canada: a population-based analysis, Lancet Rheumatol
{ 'indexed': { 'date-parts': [[2022, 10, 27]],
'date-time': '2022-10-27T04:59:46Z',
'timestamp': 1666846786484},
'reference-count': 35,
'publisher': 'Elsevier BV',
'license': [ { 'start': { 'date-parts': [[2022, 10, 1]],
'date-time': '2022-10-01T00:00:00Z',
'timestamp': 1664582400000},
'content-version': 'tdm',
'delay-in-days': 0,
'URL': 'https://www.elsevier.com/tdm/userlicense/1.0/'},
{ 'start': { 'date-parts': [[2022, 10, 1]],
'date-time': '2022-10-01T00:00:00Z',
'timestamp': 1664582400000},
'content-version': 'stm-asf',
'delay-in-days': 0,
'URL': 'https://doi.org/10.15223/policy-017'},
{ 'start': { 'date-parts': [[2022, 10, 1]],
'date-time': '2022-10-01T00:00:00Z',
'timestamp': 1664582400000},
'content-version': 'stm-asf',
'delay-in-days': 0,
'URL': 'https://doi.org/10.15223/policy-037'},
{ 'start': { 'date-parts': [[2022, 10, 1]],
'date-time': '2022-10-01T00:00:00Z',
'timestamp': 1664582400000},
'content-version': 'stm-asf',
'delay-in-days': 0,
'URL': 'https://doi.org/10.15223/policy-012'},
{ 'start': { 'date-parts': [[2022, 10, 1]],
'date-time': '2022-10-01T00:00:00Z',
'timestamp': 1664582400000},
'content-version': 'stm-asf',
'delay-in-days': 0,
'URL': 'https://doi.org/10.15223/policy-029'},
{ 'start': { 'date-parts': [[2022, 10, 1]],
'date-time': '2022-10-01T00:00:00Z',
'timestamp': 1664582400000},
'content-version': 'stm-asf',
'delay-in-days': 0,
'URL': 'https://doi.org/10.15223/policy-004'}],
'content-domain': { 'domain': [ 'clinicalkey.fr', 'clinicalkey.jp', 'clinicalkey.com.au', 'clinicalkey.es',
'clinicalkey.com', 'elsevier.com', 'sciencedirect.com'],
'crossmark-restriction': True},
'published-print': {'date-parts': [[2022, 10]]},
'DOI': '10.1016/j.semarthrit.2022.152108',
'type': 'journal-article',
'created': { 'date-parts': [[2022, 10, 26]],
'date-time': '2022-10-26T23:46:53Z',
'timestamp': 1666828013000},
'page': '152108',
'update-policy': 'http://dx.doi.org/10.1016/elsevier_cm_policy',
'source': 'Crossref',
'is-referenced-by-count': 0,
'title': 'Factors Associated with COVID-19 Breakthrough Infection Among Vaccinated Patients with Rheumatic '
'Diseases: A Cohort Study',
'prefix': '10.1016',
'author': [ {'given': 'Naomi J.', 'family': 'Patel', 'sequence': 'first', 'affiliation': []},
{'given': 'Xiaosong', 'family': 'Wang', 'sequence': 'additional', 'affiliation': []},
{'given': 'Xiaoqing', 'family': 'Fu', 'sequence': 'additional', 'affiliation': []},
{'given': 'Yumeko', 'family': 'Kawano', 'sequence': 'additional', 'affiliation': []},
{'given': 'Claire', 'family': 'Cook', 'sequence': 'additional', 'affiliation': []},
{'given': 'Kathleen M.M.', 'family': 'Vanni', 'sequence': 'additional', 'affiliation': []},
{'given': 'Grace', 'family': 'Qian', 'sequence': 'additional', 'affiliation': []},
{'given': 'Emily', 'family': 'Banasiak', 'sequence': 'additional', 'affiliation': []},
{'given': 'Emily', 'family': 'Kowalski', 'sequence': 'additional', 'affiliation': []},
{'given': 'Yuqing', 'family': 'Zhang', 'sequence': 'additional', 'affiliation': []},
{'given': 'Jeffrey A.', 'family': 'Sparks', 'sequence': 'additional', 'affiliation': []},
{ 'ORCID': 'http://orcid.org/0000-0003-4708-7038',
'authenticated-orcid': False,
'given': 'Zachary S.',
'family': 'Wallace',
'sequence': 'additional',
'affiliation': []}],
'member': '78',
'reference': [ { 'key': '10.1016/j.semarthrit.2022.152108_bib0001',
'doi-asserted-by': 'crossref',
'first-page': 'e430',
'DOI': '10.1016/S2665-9913(22)00096-0',
'article-title': 'Vaccine effectiveness against SARS-CoV-2 infection and severe outcomes '
'among individuals with immune-mediated inflammatory diseases tested '
'between March 1 and Nov 22, 2021, in Ontario, Canada: a '
'population-based analysis',
'volume': '4',
'author': 'Widdifield',
'year': '2022',
'journal-title': 'Lancet Rheumatol'},
{ 'key': '10.1016/j.semarthrit.2022.152108_bib0002',
'doi-asserted-by': 'crossref',
'first-page': '289',
'DOI': '10.1136/annrheumdis-2021-221326',
'article-title': 'Clinical characteristics and outcomes of COVID-19 breakthrough '
'infections among vaccinated patients with systemic autoimmune rheumatic '
'diseases',
'volume': '81',
'author': 'Cook',
'year': '2022',
'journal-title': 'Ann Rheum Dis'},
{ 'key': '10.1016/j.semarthrit.2022.152108_bib0003',
'doi-asserted-by': 'crossref',
'DOI': '10.1016/j.coph.2022.102243',
'article-title': 'Immunogenicity, breakthrough infection, and underlying disease flare '
'after SARS-CoV-2 vaccination among individuals with systemic autoimmune '
'rheumatic diseases',
'volume': '65',
'author': 'Paik',
'year': '2022',
'journal-title': 'Curr Opin Pharmacol'},
{ 'key': '10.1016/j.semarthrit.2022.152108_bib0004',
'doi-asserted-by': 'crossref',
'DOI': '10.1136/rmdopen-2021-002187',
'article-title': 'SARS-CoV-2 Breakthrough Infections Among Vaccinated Individuals with '
'Rheumatic Disease: Results From the COVID-19 Global Rheumatology '
'Alliance Provider Registry',
'volume': '8',
'author': 'Liew',
'year': '2022',
'journal-title': 'RMD Open'},
{ 'key': '10.1016/j.semarthrit.2022.152108_bib0005',
'doi-asserted-by': 'crossref',
'first-page': '1652',
'DOI': '10.1016/j.cmi.2021.06.036',
'article-title': 'BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully '
'vaccinated hospitalized COVID-19 patients in Israel',
'volume': '27',
'author': 'Brosh-Nissimov',
'year': '2021',
'journal-title': 'Clin Microbiol Infect'},
{ 'key': '10.1016/j.semarthrit.2022.152108_bib0006',
'doi-asserted-by': 'crossref',
'first-page': '1248',
'DOI': '10.1080/13696998.2021.2002063',
'article-title': 'Evaluation of COVID-19 vaccine breakthrough infections among '
'immunocompromised patients fully vaccinated with BNT162b2',
'volume': '24',
'author': 'Di Fusco',
'year': '2021',
'journal-title': 'J Med Econ'},
{ 'key': '10.1016/j.semarthrit.2022.152108_bib0007',
'doi-asserted-by': 'crossref',
'first-page': '1156',
'DOI': '10.1136/annrheumdis-2020-217888',
'article-title': 'Clinical characteristics and outcomes of patients with coronavirus '
'disease 2019 (COVID-19) and rheumatic disease: a comparative cohort '
"study from a US 'hot spot'",
'volume': '79',
'author': "D'Silva",
'year': '2020',
'journal-title': 'Ann Rheum Dis'},
{ 'key': '10.1016/j.semarthrit.2022.152108_bib0008',
'article-title': 'Coronavirus disease 2019 outcomes among patients with rheumatic '
'diseases 6 months into the pandemic',
'author': 'Serling-Boyd',
'year': '2020',
'journal-title': 'Ann Rheum Dis'},
{ 'key': '10.1016/j.semarthrit.2022.152108_bib0009',
'doi-asserted-by': 'crossref',
'unstructured': 'Deepak P, Kim W, Paley MA, et al. Glucocorticoids and B Cell Depleting '
'Agents Substantially Impair Immunogenicity of mRNA Vaccines to '
'SARS-CoV-2. medRxiv2021:1-41.',
'DOI': '10.1101/2021.04.05.21254656'},
{ 'key': '10.1016/j.semarthrit.2022.152108_bib0010',
'doi-asserted-by': 'crossref',
'first-page': '1255',
'DOI': '10.1136/annrheumdis-2021-221244',
'article-title': 'Impact of disease-modifying antirheumatic drugs on vaccine '
'immunogenicity in patients with inflammatory rheumatic and '
'musculoskeletal diseases',
'volume': '80',
'author': 'Friedman',
'year': '2021',
'journal-title': 'Ann Rheum Dis'},
{ 'key': '10.1016/j.semarthrit.2022.152108_bib0011',
'doi-asserted-by': 'crossref',
'first-page': '1339',
'DOI': '10.1136/annrheumdis-2021-220597',
'article-title': 'Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine '
'in immune-mediated inflammatory disease',
'volume': '80',
'author': 'Haberman',
'year': '2021',
'journal-title': 'Ann Rheum Dis'},
{ 'key': '10.1016/j.semarthrit.2022.152108_bib0012',
'doi-asserted-by': 'crossref',
'first-page': '33',
'DOI': '10.1002/art.41914',
'article-title': 'Humoral and Cellular Immune Responses to SARS-CoV-2 Infection and '
'Vaccination in Autoimmune Disease Patients With B Cell Depletion',
'volume': '74',
'author': 'Simon',
'year': '2022',
'journal-title': 'Arthritis Rheumatol'},
{ 'key': '10.1016/j.semarthrit.2022.152108_bib0013',
'article-title': 'Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in '
'adult patients with autoimmune inflammatory rheumatic diseases and in '
'the general population: a multicentre study',
'author': 'Furer',
'year': '2021',
'journal-title': 'Ann Rheum Dis'},
{ 'key': '10.1016/j.semarthrit.2022.152108_bib0014',
'doi-asserted-by': 'crossref',
'first-page': '145',
'DOI': '10.1136/annrheumdis-2021-221217',
'article-title': 'SARS-CoV-2 infection after vaccination in patients with inflammatory '
'rheumatic and musculoskeletal diseases',
'volume': '81',
'author': 'Lawson-Tovey',
'year': '2022',
'journal-title': 'Ann Rheum Dis'},
{ 'key': '10.1016/j.semarthrit.2022.152108_bib0015',
'doi-asserted-by': 'crossref',
'article-title': 'COVID-19 infection and hospitalisation risk according to vaccination '
'status and DMARD treatment in patients with rheumatoid arthritis',
'author': 'Cordtz',
'year': '2022',
'journal-title': 'Rheumatology (Oxford)',
'DOI': '10.1093/rheumatology/keac241'},
{ 'key': '10.1016/j.semarthrit.2022.152108_bib0016',
'doi-asserted-by': 'crossref',
'first-page': 'e417',
'DOI': '10.1016/S2665-9913(22)00102-3',
'article-title': 'Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant '
'in vaccinated patients with immune-mediated inflammatory diseases using '
'immunosuppressants: a substudy of two prospective cohort studies',
'volume': '4',
'author': 'Boekel',
'year': '2022',
'journal-title': 'Lancet Rheumatol'},
{ 'key': '10.1016/j.semarthrit.2022.152108_bib0017',
'doi-asserted-by': 'crossref',
'first-page': '153',
'DOI': '10.1001/jamainternmed.2021.7024',
'article-title': 'Association Between Immune Dysfunction and COVID-19 Breakthrough '
'Infection After SARS-CoV-2 Vaccination in the US',
'volume': '182',
'author': 'Sun',
'year': '2022',
'journal-title': 'JAMA Intern Med'},
{ 'key': '10.1016/j.semarthrit.2022.152108_bib0018',
'unstructured': 'COVID-19 Vaccines for People who are Moderately or Severely '
'Immunocompromised. (Accessed July 5, 2022, at '
'https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/immuno.html#:∼:text=For%20people%20who%20are%20immunocompromised,may%20have%20decreased%20over%20time.)'},
{ 'key': '10.1016/j.semarthrit.2022.152108_bib0019',
'unstructured': 'Massachusetts Immunization Information System (MIIS). (Accessed July 5, '
'2022, at '
'https://www.mass.gov/massachusetts-immunization-information-system-miis.)'},
{ 'key': '10.1016/j.semarthrit.2022.152108_bib0020',
'unstructured': 'Latest Data on COVID-19 Vaccinations by Race/Ethnicity. (Accessed July '
'5, 2022, at '
'https://www.kff.org/coronavirus-covid-19/issue-brief/latest-data-on-covid-19-vaccinations-by-race-ethnicity/.)'},
{ 'key': '10.1016/j.semarthrit.2022.152108_bib0021',
'doi-asserted-by': 'crossref',
'first-page': 'R32',
'DOI': '10.1186/ar3260',
'article-title': 'Validation of rheumatoid arthritis diagnoses in health care utilization '
'data',
'volume': '13',
'author': 'Kim',
'year': '2011',
'journal-title': 'Arthritis Res Ther'},
{ 'key': '10.1016/j.semarthrit.2022.152108_bib0022',
'first-page': '1044',
'article-title': 'Calculating the Benefits of a Research Patient Data Repository',
'author': 'Nalichowski',
'year': '2006',
'journal-title': 'AMIA Annu Symp Proc'},
{ 'key': '10.1016/j.semarthrit.2022.152108_bib0023',
'doi-asserted-by': 'crossref',
'first-page': '373',
'DOI': '10.1016/0021-9681(87)90171-8',
'article-title': 'A new method of classifying prognostic comorbidity in longitudinal '
'studies: Development and validation',
'volume': '40',
'author': 'Charlson',
'year': '1987',
'journal-title': 'J Chron Dis'},
{ 'key': '10.1016/j.semarthrit.2022.152108_bib0024',
'unstructured': 'Tracking the Omicron variant in Massachusetts. (Accessed July 5, 2022, '
'at '
'https://www.broadinstitute.org/news/tracking-omicron-variant-massachusetts.)'},
{ 'key': '10.1016/j.semarthrit.2022.152108_bib0025',
'year': '2022',
'journal-title': 'Centers for Disease Control and Prevention'},
{ 'key': '10.1016/j.semarthrit.2022.152108_bib0026',
'doi-asserted-by': 'crossref',
'DOI': '10.1136/rmdopen-2022-002279',
'article-title': 'Clinical outcomes of breakthrough COVID-19 after booster vaccination in '
'patients with systemic rheumatic diseases',
'volume': '8',
'author': 'Fragoulis',
'year': '2022',
'journal-title': 'RMD Open'},
{ 'key': '10.1016/j.semarthrit.2022.152108_bib0027',
'doi-asserted-by': 'crossref',
'first-page': '1345',
'DOI': '10.1136/annrheumdis-2021-220781',
'article-title': 'SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote '
'humoral immune responses in the presence of T-cell-mediated immunity',
'volume': '80',
'author': 'Mrak',
'year': '2021',
'journal-title': 'Ann Rheum Dis'},
{ 'key': '10.1016/j.semarthrit.2022.152108_bib0028',
'doi-asserted-by': 'crossref',
'first-page': '1990',
'DOI': '10.1038/s41591-021-01507-2',
'article-title': 'Cellular and humoral immune responses following SARS-CoV-2 mRNA '
'vaccination in patients with multiple sclerosis on anti-CD20 therapy',
'volume': '27',
'author': 'Apostolidis',
'year': '2021',
'journal-title': 'Nat Med'},
{ 'key': '10.1016/j.semarthrit.2022.152108_bib0029',
'doi-asserted-by': 'crossref',
'article-title': 'COVID-19 vaccine effectiveness against omicron (B.1.1.529) variant '
'infection and hospitalisation in patients taking immunosuppressive '
'medications: a retrospective cohort study',
'author': 'Risk',
'year': '2022',
'journal-title': 'The Lancet Rheumatology',
'DOI': '10.1016/S2665-9913(22)00216-8'},
{ 'key': '10.1016/j.semarthrit.2022.152108_bib0030',
'article-title': 'Associations of baseline use of biologic or targeted synthetic DMARDs '
'with COVID-19 severity in rheumatoid arthritis: Results from the '
'COVID-19 Global Rheumatology Alliance physician registry',
'author': 'Sparks',
'year': '2021',
'journal-title': 'Ann Rheum Dis'},
{ 'key': '10.1016/j.semarthrit.2022.152108_bib0031',
'doi-asserted-by': 'crossref',
'first-page': 'e419',
'DOI': '10.1016/S2665-9913(21)00059-X',
'article-title': 'COVID-19 outcomes in patients with inflammatory rheumatic and '
'musculoskeletal diseases treated with rituximab: a cohort study',
'volume': '3',
'author': 'Avouac',
'year': '2021',
'journal-title': 'Lancet Rheumatol'},
{ 'key': '10.1016/j.semarthrit.2022.152108_bib0032',
'doi-asserted-by': 'crossref',
'article-title': 'Postvaccination antibody titres predict protection against COVID-19 in '
'patients with autoimmune diseases: survival analysis in a prospective '
'cohort',
'author': 'Ahmed',
'year': '2022',
'journal-title': 'Ann Rheum Dis',
'DOI': '10.1136/annrheumdis-2021-221922'},
{ 'key': '10.1016/j.semarthrit.2022.152108_bib0033',
'doi-asserted-by': 'crossref',
'first-page': '191',
'DOI': '10.1038/s41584-022-00755-x',
'article-title': 'COVID-19 in people with rheumatic diseases: risks, outcomes, treatment '
'considerations',
'volume': '18',
'author': 'Grainger',
'year': '2022',
'journal-title': 'Nat Rev Rheumatol'},
{ 'key': '10.1016/j.semarthrit.2022.152108_bib0034',
'doi-asserted-by': 'crossref',
'first-page': '105',
'DOI': '10.1056/NEJMoa2115463',
'article-title': 'Comparative Effectiveness of BNT162b2 and mRNA-1273 Vaccines in U.S. '
'Veterans',
'volume': '386',
'author': 'Dickerman',
'year': '2022',
'journal-title': 'N Engl J Med'},
{ 'key': '10.1016/j.semarthrit.2022.152108_bib0035',
'doi-asserted-by': 'crossref',
'first-page': '1700',
'DOI': '10.15585/mmwr.mm7049a2',
'article-title': 'Comparative Effectiveness and Antibody Responses to Moderna and '
'Pfizer-BioNTech COVID-19 Vaccines among Hospitalized Veterans — Five '
'Veterans Affairs Medical Centers, United States, February 1–September '
'30, 2021',
'volume': '70',
'author': 'Bajema',
'year': '2021',
'journal-title': 'MMWR Morb Mortal Wkly Rep'}],
'container-title': 'Seminars in Arthritis and Rheumatism',
'original-title': [],
'language': 'en',
'link': [ { 'URL': 'https://api.elsevier.com/content/article/PII:S0049017222001597?httpAccept=text/xml',
'content-type': 'text/xml',
'content-version': 'vor',
'intended-application': 'text-mining'},
{ 'URL': 'https://api.elsevier.com/content/article/PII:S0049017222001597?httpAccept=text/plain',
'content-type': 'text/plain',
'content-version': 'vor',
'intended-application': 'text-mining'}],
'deposited': { 'date-parts': [[2022, 10, 26]],
'date-time': '2022-10-26T23:47:13Z',
'timestamp': 1666828033000},
'score': 1,
'resource': {'primary': {'URL': 'https://linkinghub.elsevier.com/retrieve/pii/S0049017222001597'}},
'subtitle': [],
'short-title': [],
'issued': {'date-parts': [[2022, 10]]},
'references-count': 35,
'alternative-id': ['S0049017222001597'],
'URL': 'http://dx.doi.org/10.1016/j.semarthrit.2022.152108',
'relation': {},
'ISSN': ['0049-0172'],
'subject': ['Anesthesiology and Pain Medicine', 'Rheumatology'],
'container-title-short': 'Seminars in Arthritis and Rheumatism',
'published': {'date-parts': [[2022, 10]]},
'assertion': [ {'value': 'Elsevier', 'name': 'publisher', 'label': 'This article is maintained by'},
{ 'value': 'Factors Associated with COVID-19 Breakthrough Infection Among Vaccinated '
'Patients with Rheumatic Diseases: A Cohort Study',
'name': 'articletitle',
'label': 'Article Title'},
{ 'value': 'Seminars in Arthritis and Rheumatism',
'name': 'journaltitle',
'label': 'Journal Title'},
{ 'value': 'https://doi.org/10.1016/j.semarthrit.2022.152108',
'name': 'articlelink',
'label': 'CrossRef DOI link to publisher maintained version'},
{'value': 'article', 'name': 'content_type', 'label': 'Content Type'},
{ 'value': '© 2022 Elsevier Inc. All rights reserved.',
'name': 'copyright',
'label': 'Copyright'}],
'article-number': '152108'}